Bill RohnBill Rohn has nearly 40 years of experience as a senior executive in the pharmaceutical and biotech industry. He retired in January of 2005 from the position of Chief Operating Officer at Biogen-Idec, one of the larger global biotech companies, which was formed by the merger in 2003 of IDEC Pharmaceuticals and Biogen Inc. Prior to serving as COO of the combined company, Bill was the President and Chief Operating Officer of IDEC Pharmaceuticals, having joined the company in 1993 as Sr. Vice President of Commercial and Corporate Development.
Before moving to the fledgling biotech industry in its early days, Bill spent approximately 25 years in the pharmaceutical sector in a variety of commercial operating roles of increasing responsibility with such companies as Abbott Laboratories, Bristol-Myers Squibb Co., and Adria Laboratories (now part of Pfizer).
Although he retired from a full-time operating role in 2005, Bill remains active in the biotech industry serving on the Board of Directors of three publically traded biotech companies (Elan Corporation, Metabasis Therapeutics Inc., and Cerus Corporation) and one private biotech company (Cebix Inc.).
Michael C. Scaife, Ph.D.
Michael has worked for 26 years in a variety of device, drug and biopharma companies in both Europe and the US in leadership roles in product development, including regulatory affairs, clinical, drug safety and quality. The companies that he has worked for include: Johnson & Johnson, Zambon, Sandoz/Novartis, Elan and Chiron -in this last company before he became a full-time consultant, he had the role of Senior VP for Drug Safety, Quality & Product Improvement, and Global Regulatory Affairs.
Michael Wiebe, Ph.D.
President, Quantum Consulting, LLC
Dr. Wiebe is Founder and President of Quantum Consulting based in Redwood City, California. His consulting practice is focused on biotechnology development, biosafety, manufacturing, quality assurance and GMP compliance. He has 24 years of experience in the CMC aspects of biotechnology and has participated as a member of numerous product development teams that were successful in bringing new biotech products through the development pipeline and into commercial life. He has held positions at the following companies: Genentech, 1984-1998 (Senior Scientist, Cell Culture Development; Sr. Director, Quality Control); BioReliance, 1998-2001 (Chief Scientific Officer and Vice President of Quality & Regulatory Affairs); IDEC Pharmaceuticals, 2001-2003 (Vice President of Quality); Biogen Idec, 2003-2005 (Vice President of Corporate Quality & Drug Compliance); Novartis (formerly Chiron), 2005-2007 (Vice President of Quality Assurance for U.S. Biopharmaceutical Operations). Earlier in his career Dr. Wiebe held positions at Duke University Medical School (Research Fellow), Cornell University Medical College (Assistant & Associate Professor), and the New York Blood Center (Associate Investigator). He received his Ph.D. in Microbiology from the University of Kansas and his B.S. in Natural Sciences from Sterling College (Kansas).